Ensuring patient access to innovative treatment options
Ensuring patient access to innovative treatment options
What is Happening With Medicare/MolDX?
On August 10, 2023, MolDX: Molecular Testing for Solid Organ Allograft Rejection released two proposed Local Coverage Determinations (LCDs) that impact Medicare coverage for non-invasive diagnostic tests used for organ transplant monitoring: Palmetto GBA and Noridian. Noridian and Palmetto have opened the comment period to determine the proposed changes to the Local Coverage Determination (LCD) for Molecular Diagnostics for Transplant.
We would like to share some details and inform you of the opportunity to voice your opinion. Both are now open for public comment, to be submitted in writing. There is an opportunity to weigh in on the proposed coverage outlined in the LCDs.
What is Happening With Medicare/MolDX?
On August 10, 2023, MolDX: Molecular Testing for Solid Organ Allograft Rejection released two proposed Local Coverage Determinations (LCDs) that impact Medicare coverage for non-invasive diagnostic tests used for organ transplant monitoring: Palmetto GBA and Noridian.
Both are now open for public comment, to be submitted in writing. There is an opportunity to weigh in on the proposed coverage outlined in the LCDs.
Why Should This Matter to You & Your Patients?
The proposed LCD would be a major step backwards for transplant patient care as they are inconsistent with current medical practice and guidelines. The proposed LCD that coverage would limit molecular testing for solid organ allograft assessment, hindering clinician discretion and restricting previously available options for patient care.
Why Should This Matter to You & Your Patients?
The proposed LCD would be a major step backwards for transplant patient care as they are inconsistent with current medical practice and guidelines. The proposed LCD that coverage would limit molecular testing for solid organ allograft assessment, hindering clinician discretion and restricting previously available options for patient care.
What Changes Were Made?
1. You can see changes directly in each LCD:
a. Palmetto GBA (MolDX)
LCD # DL38568
b. Noridian
LCD # DL38629
2. Additional Resources:
a. Bruce Quinn, MD, PhD (not affiliated with CareDx) drafted a
redline of the LCD
indicating which changes occurred in the August 10, 2023 revision
You can see the proposed LCD online:
Palmetto GBA (MolDX)
Noridian
LCD # DL38568Additional Resources:
Bruce Quinn, MD, PhD (not affiliated with CareDx)
drafted
indicating which changes occurred in the August 10, 2023 revision
You can see the proposed LCD online:
Palmetto GBA (MolDX)
Noridian
LCD # DL38568Additional Resources:
Bruce Quinn, MD, PhD (not affiliated with CareDx)
drafted
indicating which changes occurred in the August 10, 2023 revision
How Can You Help?
Submit your written public comments via email by clicking the button below.
Palmetto GBA (MolDX) and Noridian due on September 23, 2023. Additional scientific summary is also included on the other pages for your reference.
How Can You Help?
Submit your written public comments via email by clicking the button below.
Palmetto GBA (MolDX) and Noridian due on September 23, 2023. Additional scientific summary is also included on the other pages for your reference.
How Can You Help?
• Submit your written public comments via email by clicking here. Comments will be sent to both Palmetto GBA (MolDX) and Noridian due on September 23, 2023. Additional scientific summary is also included in the link for your reference.
Thank you for your continued support of innovation in transplantation. We look forward to connecting soon.
Sincerely,
Your CareDx Team